Download PDF
Endoscopy 2001; 33(3): 245-252
DOI: 10.1055/s-2001-12795
Original Article

Thyroid Function, Thyroid Immunoglobulin Status, and Urinary Iodine Excretion after Enteral Contrast-Agent Administration by Endoscopic Retrograde Cholangiopancreatography

W. J. Fassbender1 , C. Vogel2 , W. Doppl2 , H. Stracke2 , R. G. Bretzel2 , H. U. Klör2
  • 1 Medizinische Klinik III, Universitätsklinikum der RWTH, Aachen, Germany
  • 2 Medizinische Klinik und Poliklinik III, Justus-Liebig-Universität Giessen, Giessen, Germany
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Background and Study Aims: The aim of this study was to examine the occurrence of clinically relevant changes in thyroid function after enteral administration of contrast agent by endoscopic retrograde cholangiopancreatography (ERCP).

Patients and Methods: In this study 70 patients without a history of thyroid disease who had not recently undergone thyroid-specific or thyroid-influencing therapy were examined. Patients were examined on two or three occasions using a standardized questionnaire regarding symptoms of hypothyroidism and hyperthyroidism. The parameters of thyroid function (TT3, TT4, FT4, thyroid-stimulating hormone (TSH)) and urinary iodine excretion were measured on day 0 and on day 21 post-ERCP, and in 23 patients additionally on day 42 post-ERCP. Based on ultrasonographic results, four groups differing in thyroid morphology were distinguished.

Results: The data show that an average amount of only 4.7 g of enterally applied iodine is associated with a lasting decrease of TSH, especially in patients with enlarged organs with nodular transformation. As far as TT3 is concerned, there was a significant increase in all patient groups; regarding FT4 we only observed a marked increase in the group with enlarged, nodular thyroid glands. There was a notable increase in urinary iodine excretion on day 21, and a further increase on day 42 post-ERCP. Clinical symptoms of hyperthyroidism did not occur.

Conclusions: We conclude that before administration of iodine-containing contrast agent for ERCP in patients without a history of thyroid disease, thyroid ultrasonographic examination, rather than TSH measurements, should be performed, in order to identify patients already at risk for hyperthyroidism before diagnostic enteral contrast-medium application.

References

  • 1 Coinded J F. Nouvelles recherches sur les éffets de l'iode, et sur les précautions à suivre dans le traitement de goitre par le nouveau remède.  Bibl Univ Sci Belles Lettres Arts. 1821;  16 140-152
    PubMedGoogle Scholar
  • 2 Rajatanavin R, Safran M, Stoller W A, et al. Five patients with iodine-induced hyperthyroidism.  Am J Med. 1984;  77 378-384
    CrossrefPubMedGoogle Scholar
  • 3 Blum M, Weinberg L, Shenkman L, Hollander C S. Hyperthyroidism after iodinated contrast medium.  N Engl J Med. 1974;  291 24-25
    PubMedGoogle Scholar
  • 4 Herrmann J, Krüskemper H L. Gefährdung von Patienten mit latenter und manifester Hyperthyreose durch jodhaltige Röntgenkontrastmittel und Medikamente.  Dtsch Med Wochenschr. 1978;  103 1434-1443
    PubMedGoogle Scholar
  • 5 Steidle B. Iodine-induced hyperthyroidism after contrast media: animal experimental and clinical studies. In: Taenzer V, Wende S, eds. Recent developments in nonionic contrast media.  Stuttgart; Thieme 1989: 6-14
    Google Scholar
  • 6 Bauhofer G, Hausen A, Riccabona G. Thyroxin und Trijodthyronin im Serum Euthyreoter nach Röntgenuntersuchungen mit jodhaltigen Kontrastmitteln.  Münch Med Wochenschr. 1978;  120 927-928
    PubMedGoogle Scholar
  • 7 Bürgi H, Wimpfheimer C, Burger A, et al. Changes of circulating thyroxine, trijodthyronine and reverse trijodthyronine after radiographic contrast agents.  J Clin Endocrinol Metab. 1976;  43 1203-1210
    PubMedGoogle Scholar
  • 8 Mann K, Rendl J, Busley R, et al. Systemic iodine absorption during endoscopic application of radiographic contrast agents for endoscopic retrograde cholangiopancreaticography.  Eur J Endocrinol. 1994;  30 498-501
    PubMedGoogle Scholar
  • 9 Rendl J, Schmidt T h, Börner W. Beeinflussen nichtionische Röntgenkontrastmittel die Schilddrüsenparameter?. In: Börner W, Weinheimer B, eds. Schilddrüse 1989.  Berlin; Walter de Gruyter 1991: 53-62
    Google Scholar
  • 10 Bottermann P. Jodinduzierte Hyperthyreose.  Med Klin. 1986;  81 753-757
    PubMedGoogle Scholar
  • 11 Sable R A, Rosenthal W S, Siegel J, et al. Absorption of contrast media during ERCP.  Am J Dig. 1983;  28 801-806
    PubMedGoogle Scholar
  • 12 Mönig H, Arendt T, Eggers S, et al. Iodine absorption in patients undergoing ERCP compared with coronary angiography.  Gastrointest Endosc. 1999;  50 79-81
    PubMedGoogle Scholar
  • 13 Pfannenstiel P, Saller B. Schilddrüsenkrankheiten. Diagnose und Therapie.  Berlin; Berliner Med Verl Anst, 1991 Second edition
    Google Scholar
  • 14 Brunn J, Block U, Ruf G, et al. Volumetrie der Schilddrüsenlappen mittels real-time Sonographie.  Dtsch Med Wochenschr. 1981;  106 1338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Olbricht T, Schmitka T, Mellinghoff U, et al. Sonographische Bestimmung der Schilddrüsenvolumina bei Schilddrüsengesunden.  Dtsch Med Wochenschr. 1993;  108 1355
    PubMedGoogle Scholar
  • 16 Wawschinek O, Eber O, Petek W, et al. Bestimmung der Harnjodausscheidung mittels einer modifizierten Cer-Arsenitmethode. Berichte der öGKC 1985: 13-15
    Google Scholar
  • 17 Meng W. Deutschland - ein Jodmangelgebiet.  Deutsches ärzteblatt. 1994;  19 1366-1370
    PubMedGoogle Scholar
  • 18 Frey H MM, Rosenlund B, Torgersen J P. Value of single urine specimens in estimation of 24 hour iodine excretion.  Acta Endocrinol. 1973;  72 287-292
    PubMedGoogle Scholar
  • 19 Schmid M, Schulthess C, Bürgi H, Studer H. Jodmangel ist in der Schweiz noch immer endemisch.  Schweiz Med Wochenschr. 1980;  110 1290-1295
    PubMedGoogle Scholar
  • 20 Jensen D R. Efficiency and robustness in the use of repeated measurements.  Biometrics. 1982;  38 813-825
    PubMedGoogle Scholar
  • 21 Catellier D J, Muller K E. Tests for Gaussian repeated measures with missing data in small samples.  Stat Med. 2000;  19 1101-1114
    CrossrefPubMedGoogle Scholar
  • 22 Habermann J, Heinze H G, Horn K, et al. Alimentärer Jodmangel in der Bundesrepublik Deutschland.  Dtsch Med Wochenschr. 1975;  100 1937
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Carstensen F, Wurbs D. Contrast medium resorption in ERCP.  Z Gastroenterol. 1993;  31 369-375
    PubMedGoogle Scholar
  • 24 Hopper K D, Wegert S J, Hallgren S E. Renal excretion of endoscopic retrograde cholangiopancreaticography injected contrast. A common phenomenon.  Invest Radiol. 1989;  24 394-396
    PubMedGoogle Scholar
  • 25 Roti E, Vagenakis A G. Effect of excess iodide: clinical aspects. In: Braverman LE, Utiger RD, eds. Werner's the thyroid.  Philadelphia; JB Lippincott 1991: 390
    Google Scholar
  • 26 Hehrmann R. Physiologie und Pathophysiologie des intrathreoidalen Jodstoffwechsels I & II.  Therapiewoche. 1981;  31 1478 - 1491, 1491 - 1502
    PubMedGoogle Scholar
  • 27 Gutekunst R, Magiera U, Teichert H M. Iodine deficiency in Germany.  Med Klin. 1993;  88 525-528
    PubMedGoogle Scholar
  • 28 Wolff J, Chaikoff I L. The inhibitory action of iodide upon organic binding of iodine by the normal thyroid gland.  Biol Chem. 1948;  172 855-856
    PubMedGoogle Scholar
  • 29 Wu S Y, Chopra I J, Solomon D H, Bennet L P. Changes in circulating iodothyronines in euthyroid and hyperthroid subjects given iodopodate (Oragrafin), agents for oral cholecystography.  J Clin Endocrinol Metab. 1978;  46 691-697
    PubMedGoogle Scholar
  • 30 Scherbaum W A, Rosenau K O, Seif F J. Antikörper gegen Schilddrüsenmikrosomen und Thyreoglobulin beim Morbus Basedow und anderen Erkrankungen.  Med Welt. 1979;  30 1401-1406
    PubMedGoogle Scholar
  • 31 Braverman L E. Classification of thyreotoxicosis and iodine-induced hyperthyroidism. In: Reinwein D, Scriba PC, eds. The various types of hyperthyroidism.  Munich; Urban and Schwarzenberg 1990: 45-56
    Google Scholar
  • 32 Braverman L E. Iodine-induced thyroid disease.  Acta Med Austriaca. 1990;  17 29-33
    PubMedGoogle Scholar
  • 33 Fradkin J E, Wolff J. Iodide-induced thyrotoxicosis.  Medicine (Baltimore). 1983;  62 1-20
    PubMedGoogle Scholar
  • 34 Klein I, Levey G S. Iodide excess and thyroid function.  Ann Intern Med. 1983;  98 406-407
    PubMedGoogle Scholar

W. J. Fassbender, M.D.

Medizinische Klinik III
Universitätsklinikum der RWTH
Abt. Gastroenterologie und Stoffwechselkrankheiten

Pauwelsstrasse 30
52 074 Aachen
Germany


Fax: Fax:+ 49-241-88-88455

Email: E-mail:wjfassbender@post.klinikum.rwth-aachen.de

      >